Clopidogrel Resistance in Stroke Patients From Different Ethnicities

Ziv Hospital

Status: Unknown

Conditions: Ischemic Stroke; Clopidogrel, Poor Metabolism of

Treatments: Diagnostic Test: Quantification of platelet aggregation

Study type: Observational

Funder types: Other

Identifiers

NCT03806894

0112-17-ZIV

Details and patient eligibility

About

Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ability to provide written informed consent and to be compliant with protocol assessments.
2. Ages 18 and above inclusive
3. Both genders eligible for the study
4. Diagnosis of ischemic cerebrovascular event

Exclusion criteria

1. Pregnant patients will be excluded
2. Ages below 18
3. Patients not able to provide informed consent

Trial design

300 participants in 2 patient groups

Jewish communities

Description:

Ashkenazi, Sephardi, Ethiopian

Treatment:

Diagnostic Test: Quantification of platelet aggregation

Arab populations

Description:

Muslim, Christian, Druze

Treatment:

Diagnostic Test: Quantification of platelet aggregation